October 31, 2017 - 7:30 AM EDT
Print Email Article Font Down Font Up Charts


Earnings Review and Free Research Report: Core Laboratories’ EPS Increased 26.3%

Research Desk Line-up: Schlumberger Post Earnings Coverage

LONDON, UK / ACCESSWIRE / October 31, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Core Laboratories N.V. (NYSE: CLB), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=CLB, following the Company's disclosure of its financial results on October 23, 2017, for the third quarter of the fiscal year 2017. The Company's revenue increased 15.9% on a y-o-y basis. Our daily stock reports are accessible for free, and with those to look forward today you also will be signing up for a complimentary member's account at:

http://protraderdaily.com/register/

Get more of our free earnings reports coverage from other constituents of the Oil & Gas Equipment & Services industry. Pro-TD has currently selected Schlumberger Limited (NYSE: SLB) for due-diligence and potential coverage as the Company reported on October 20, 2017, its financial results for Q3 2017. Register for a free membership today, and be among the early birds that get access to our report on Schlumberger when we publish it.

At Pro-TD, we make it our mission to bring you news that matter about the stock you follow. Today, our research desk covers a blog story on CLB; also brushing on SLB. With the links below you can directly download the report of your stock of interest free of charge at:

http://protraderdaily.com/optin/?symbol=CLB

http://protraderdaily.com/optin/?symbol=SLB

Earnings Reviewed

For the three months ended September 30, 2017, Core Laboratories' revenues increased 15.9% to $166.25 million from $143.48 million in Q3 FY16. The revenue numbers surpassed analysts' expectations of $161 million.

During Q3 FY17, the Company's G&A expenses increased 41.4% to $11.89 million from $8.41 million in the same period of last year. For the reported quarter, Core Laboratories' D&A expenses decreased 9.4% to $6.09 million from $6.72 million in Q3 FY16. For the reported quarter, the Company's total operating expenses increased 13.8% to $138.77 million from $122.0 million in Q3 FY16.

During Q3 FY17, Core Laboratories' operating income increased 27.9% to $27.48 million from $21.49 million in the comparable period of last year. For the reported quarter, the Company's operating margin increased 160 basis points to 16.5% of revenue from 14.9% of revenue in Q3 FY16.

For the reported quarter, Core Laboratories' net income increased 26% to $21.09 million on a y-o-y basis from $16.73 million in Q3 FY16. During Q3 FY17, Core Laboratories' diluted earnings per share (EPS) increased 26.3% to $0.48 on a y-o-y basis from $0.38 in the corresponding period of last year. The diluted EPS surpassed analysts' expectations of $0.44.

Segment Details

Reservoir Description - During Q3 FY17, Core Laboratories' Reservoir Description segment's revenue decreased 3.8% to $101.44 million from $105.43 million in the same period of last year. For the reported quarter, the segment's operating income decreased 31.3% to $14.62 million from $21.27 million in Q3 FY16.

Production Enhancement - During Q3 FY17, Core Laboratories' Production Enhancement segment's revenue increased 70.3% to $64.81 million from $38.06 million in the comparable period of last year, due to an increased demand for the Company's advanced technology solutions. For the reported quarter, the segment's operating income was $12.97 million compared to $118,000 in Q3 FY16.

Balance Sheet

As on September 30, 2017, Core Laboratories' cash and cash equivalents decreased 6.7% to $13.78 million from $14.76 million as on December 31, 2016.

During Q3 FY17, the Company's net accounts receivables increased 13.4% to $129.66 million from $114.33 million in Q4 FY16.

For the reported quarter, Core Laboratories' inventory increased 2.3% to $34.50 million from $33.72 million in the fourth quarter of 2016.

During Q3 FY17, the Company's total assets increased 1.7% to $582.74 million from $573.05 million in Q4 FY16.

For the reported quarter, Core Laboratories' accounts payable increased 3.5% to $34.90 million from $33.72 million in Q4 FY16.

During Q3 FY17, the Company's long-term debts and lease obligations increased 8% to $233.86 million from $216.49 million in the fourth quarter of 2016.

During Q3 FY17, Core Laboratories' cash provided by operating activities decreased 14.3% to $29.88 million from $34.87 million in the corresponding period of last year. During Q3 FY17, the Company's capital expenditure was $4.90 million and free cash flow was 24.98 million.

Outlook

For Q4 FY17, Core Laboratories expects revenue to be $171.50 million; operating income to be $32.80 million; and EPS to be $0.58.

Stock Performance

On Monday, October 30, 2017, Core Laboratories' stock closed the trading session at $97.65, climbing 2.66% from its previous closing price of $95.12. A total volume of 1.19 million shares were exchanged during the session, which was above the 3-month average volume of 525.57 thousand shares. Shares of the Company have a PE ratio of 56.31 and have a dividend yield of 2.25%. The stock currently has a market cap of $4.31 billion.

Pro-Trader Daily:

Pro-Trader Daily (Pro-TD) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and Canadian stocks. PRO-TD has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles, and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

PRO-TD has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charter-holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by PRO-TD. PRO-TD is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

PRO-TD, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. PRO-TD, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, PRO-TD, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither PRO-TD nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://protraderdaily.com/disclaimer/.

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: [email protected]

Phone number: (917) 341.4653

Office Address: Mainzer Landstrasse 50 Frankfurt am Main, Germany 60325

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Pro-Trader Daily


Source: ACCESSWIRE Investor Awareness (October 31, 2017 - 7:30 AM EDT)

News by QuoteMedia
www.quotemedia.com
Tags:

Legal Notice